Active Pharma Ingredients (APIs)
JPN Pharma is a global leader in the production of large-volume generic Active Pharmaceutical Ingredients (APIs), committed to upholding environmental safety and sustainability at every stage. Our facilities boast prestigious EDQM (European Directorate for the Quality of Medicines) and WHO-GMP (World Health Organization - Good Manufacturing Practices) approvals, underscoring our expertise in handling hazardous chemicals and executing complex reactions with meticulous precision. Supported by a dedicated R&D setup and stringent QA/QC practices, we ensure uncompromising quality across varied batch sizes and reactor volumes ranging from 5 to 8000 liters.
At JPN Pharma, sustainability is ingrained in our operational ethos. We employ environmentally responsible production methods and prioritize the use of clean fuel in our boiler operations. Our advanced equipment includes the Agitated Nutsche Filter Dryer (ANFD) and Rotary Vacuum Paddle Dryer, enabling safe and efficient production, particularly for temperature-sensitive products. Managed by JPN LLP, our Zero Liquid Discharge facility exemplifies our commitment to minimizing environmental impact.
Trusted by esteemed pharmaceutical leaders like Cipla, Glenmark, Zydus, and Abbott, JPN Pharma specializes in manufacturing APIs on a significant scale. Situated in Maharashtra, our GMP and FDA-approved facilities are dedicated to producing essential molecules that play a pivotal role in global healthcare solutions.
Our APIs are used across various therapeutic categories, including:

Topical antimicrobials

Cardiovascular treatments

Hypertension and heart failure management

Bone health

Benign prostatic hyperplasia

Anticonvulsants

Dementia care
JPN Pharma continues to lead the industry with a steadfast commitment to
quality, sustainability and innovation.
Name of Product :- TORSEMIDE |
DMF |
SR. NO. | CRITERIA | SPECIFICATION |
1 | Description | White to off-white, crystalline powder. |
2 | Solubility | Slightly soluble in 0.1N sodium hydroxide , in 0.1N hydrochloric acid, in alcohol, and in methanol; very slightly soluble in acetone and in chloroform; practically insoluble in water and in ether. |
3 | Identification A. By Infra red Absorption
|
B. The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the standard preparation, as obtained in the Assay |
4 | Water content | Not more than 1.0% |
5 | Residue on Ignition | Not more than 0.1% |
6 | Related compounds (By HPLC) Related compound A Related compound B Related compound C Any other impurity Total other impurity Total impurities |
Not more than 0.3% Not more than 0.2% Not more than 0.1% Not more than 0.2% Not more than 1.0% |
7 | Assay (By HPLC) | Not less than 98.0% and not more than 102.0% (on anhydrous basis) |
